Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha

European Journal of Pharmaceutical Sciences

Volumn 18, Issue 3-4, 2003, Pages 221-229

  Sánchez, Alejandro ^a   Tobío, María ^a   González, Libia ^a   Fabra, Angels ^b   Alonso, María J ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Institut de Recerca Oncologica   (Spain)

Author keywords

Controlled release; Cytokine; Interferon; Microspheres; Nanospheres; Protein delivery

Indexed keywords

BIOASSAY; BIODEGRADATION; ENCAPSULATION; EVAPORATION; INTERFERONS; NANOSTRUCTURED MATERIALS; SOLVENTS;

LONG-TERM DELIVERY VEHICLES;

DRUG PRODUCTS;

ALPHA INTERFERON; DRUG VEHICLE; MICROSPHERE; NANOPARTICLE; OIL; POLOXAMER; POLYGLACTIN; PROTEIN; RESOMER; WATER;

ARTICLE; BIOASSAY; BIODEGRADATION; CONTROLLED STUDY; CYTOSTASIS; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 0037343587     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(03)00019-8     Document Type: Article

References (27)

1. Audran R., Men Y., Johansen P., Gander B., Corradin G. Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents. Pharm. Res. 15:1998;1111-1116.
2. Beilharz M.W. Therapeutic potential for orally administered type 1 interferons. Pharm. Sci. Tech. Today. 3:2000;193-197.
3. Blanco D., Alonso M.J. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur. J. Pharm. Biopharm. 43:1997;83-94.
4. Bocci V. Physicochemical and biological properties of interferons and their potential uses in drug delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;91-133.
5. Chen L., Apte R.N., Cohen S. Characterization of PLGA microspheres for the controlled delivery of IL-1α for tumor immunotherapy. J. Controlled Release. 43:1997;261-272.
6. Cleland J.L., Jones A.J.S. Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable microspheres. Pharm. Res. 13:1996;1464-1475.
7. Dunne M., Corrigan O.I., Ratoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials. 21:2000;1659-1668.
8. Eppstein D.A., Stewart W.E. Altered pharmacological properties of liposome-associated human interferon-alpha. J. Virol. 41:1982;575-582.
9. Fu K., Pack D.W., Klibanov A.M., Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 17:2000;100-106.
10. Hora M.S., Rana R.K., Numberg J.H., Tice T.R., Gilley R.M., Hudson M.E. Controlled release of interleukin-2 from biodegradable microspheres. Biotechnology. 8:1990;755-758.
11. Johansen P., Men Y., Audran R., Corradin G., Merkle H.P., Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm. Res. 15:1998;1103-1110.
12. Kozlowski A., Harris J.M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Controlled Release. 72:2001;217-224.
13. Morlock M., Koll H., Winter G., Kissel T. Microencapsulation of rh-erythropoietin, using biodegradable poly(D,L-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. Eur. J. Pharm. Biopharm. 43:1997;29-36.
14. Pean J., Boury F., Vernier M., Menei P., Proust J., Benoit J. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm. Res. 16:1999;1294-1299.
15. Pearlman, R., Nguyen, T.H., 1991. Analysis of protein drugs, In: V.H.L. Lee (Ed.), Peptide and Protein Drug Delivery, Marcel Dekker, New York.
16. Piscitelli S.C., Reiss W.G., Figg W.D., Petros W.P. Pharmacokinetic studies with recombinant cytokines, scientific issues and practical considerations. Clin. Pharmacokinet. 32:1997;368-381.
17. Schwendeman S.P., Cardamone M., Brandon M.R., Klibanov A., Langer R. Stability of proteins and their delivery from biodegradable polymer microspheres. Cohen S., Bernstein H. Microparticulate Systems for the Delivery of Proteins and Vaccines. 1996;Marcel Dekker, New York.
18. Schwendeman S.P., Tobio M., Joworowicz M., Alonso M.J., Langer R. New strategies for the microencapsulation of tetanus vaccine. J. Microencapsul. 15:1998;299-318.
19. Sharif S., O'Hagan D.T. A comparison of alternative methods for the determination of the levels of proteins entrapped in poly(lactide-co-glycolide) microparticles. Int. J. Pharm. 115:1995;259-263.
20. Tami J. Interleukins and interferons. Crommelin D.J.A., Sindelar R.D. Pharmaceutical Biotechnology. 1997;215-225 Harwood Academic, Amsteldijk.
21. Tobío M., Gref R., Sanchez A., Langer R., Alonso M.J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 15:1998;270-275.
22. Tobío M., Nolley J., Guo Y., McIver J., Alonso M.J. A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. Pharm. Res. 16:1999;682-688.
23. Tobío M., Sanchez A., Hoet S., Fabra A., Alonso M.J. Microspheres based on PLGA/poloxamer blends as emerging delivery vehicles for macromolecules: Application to interferon-α 12th International Symposium on Microencapsulation, London:1999.
24. Tobío M., Sánchez A., Vila A., Soriano I., Evora C., Vila-Jato J.L., Alonso M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surfaces B Biointerfaces. 18:2000;315-323.
25. Tobío M., Sanchez A., Gonzalez L.E., Fabra A., Alonso M.J. Design of biodegradable microspheres and nanospheres as new controlled delivery vehicles for interferon-alpha. IV Spanish-Portuguese conference on Controlled Drug Delivery, Vitoria-Gasteiz, Spain:2000.
26. Yang J., Cleland J.L. Factors affecting the in vitro release of recombinant human interferon-γ (rhIFN-γ) from PLGA microspheres. J. Pharm. Sci. 86:1997;908-914.
27. Yu H., Grainger D.W. Modified release of hydrophilic, hydrophobic and peptide agents from ionized amphiphilic gel networks. J. Controlled Release. 34:1995;117-127.